Diabetes Mellitus: Current Research and Future Perspectives 2nd Edition
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".
Deadline for manuscript submissions: 25 September 2024 | Viewed by 752
Special Issue Editor
Interests: diabetology; pediatric endocrinology; nutrition; obesity; bone metabolism
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The heterogeneity in age at onset and clinical presentation within the same form of diabetes, differences in the response to treatments in patients with the same phenotype, and the variability in the course of the disease require personalized management. The precision medicine approach has been applied to individuals with monogenic diabetes (i.e., MODY, neonatal diabetes) and to type 1 and type 2 diabetes to select treatments that are most likely to offer benefits and least likely to cause side effects, with improvement of clinical outcomes and economic cost saving.
In the last 10 years, genetic, metabolomic, immunologic, and other sophisticated tests have become less expensive and more widespread; therefore, it is expected that precision medicine will become increasingly applied to diabetes care.
This Special Issue of Journal of Personalized Medicine aims to highlight the current state of precision medicine applied to diabetes to show some of the latest findings and future perspectives and integrate expertise from basic science, clinical, and population-based approaches. Topics of interest include novel insights into gene testing, polymorphisms and bioinformatics, metabolites and intestinal microbiome analysis, as well as their association with the risk of disease, drug metabolism, or disease complications.
Dr. Roberto Franceschi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- diabetes treatment
- drug metabolism
- disease complications
- polymorphisms
- epigenetics
- metabolomics
- proteomics
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Exploring the relationship between insulin resistance and restrictive lung diseases in type 2 diabetes: A study on lifestyle interventions and risk factors
Authors: Mani Roshan #1,2, Christian Mudrack #1, Alba Sulaj1,2, Ekaterina von Rauchhaupt1, Lukas Seebauer1,2, Elisabeth Kliemank1,2, Zoltan Kender1,2, Julia Szendroedi1,2, Stefan Kopf1,2
Affiliation: 1Department of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.
2German Center for Diabetes Research (DZD).
